The current state of RAAS blockade in the treatment of hypertension and proteinuria

Current Cardiology Reports

Volumn 11, Issue 6, 2009, Pages 436-442

  Bakris, George L ^a   Kalaitzidis, Rigas G ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CAPTOPRIL; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL SUCCINATE; PLACEBO; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE TITRATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MICROALBUMINURIA; MORBIDITY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; URINARY EXCRETION;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 72849121689     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-009-0063-3     Document Type: Review

References (47)

1. A.S. Go G.M. Chertow D. Fan, et al. 2004 Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 1296 1305 10.1056/NEJMoa041031 1:CAS:528:DC%2BD2cXnvFSgtr8%3D 15385656 (Pubitemid 39268908)
2. J. Coresh E. Selvin L.A. Stevens, et al. 2007 Prevalence of chronic kidney disease in the United States JAMA 298 2038 2047 10.1001/jama.298.17.2038 1:CAS:528:DC%2BD2sXht1yjsLnM 17986697 (Pubitemid 350074801)
3. United States Renal Data System: 2008 ADR/Reference Tables. Available at http://www.usrds.org/reference.htm. Accessed August 2009.
4. E.J. Lewis L.G. Hunsicker R.P. Bain R.D. Rohde 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 1456 1462 10.1056/NEJM199311113292004 1:STN:280:DyaK2c%2FhvFKitQ%3D%3D 8413456 (Pubitemid 23335891)
5. Kidney Disease Outcomes Quality Initiative 2004 K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease [no authors listed] Am J Kidney Dis 43 S1 S290
6. P.A. Sarafidis N. Khosla G.L. Bakris 2007 Antihypertensive therapy in the presence of proteinuria Am J Kidney Dis 49 12 26 10.1053/j.ajkd.2006.10.014 1:CAS:528:DC%2BD2sXhsFSjsLo%3D 17185142 (Pubitemid 44918179)
7. M.J. Klag P.K. Whelton B.L. Randall, et al. 1996 Blood pressure and end-stage renal disease in men N Engl J Med 334 13 18 10.1056/ NEJM199601043340103 1:STN:280:DyaK287gsFakug%3D%3D 7494564 (Pubitemid 26012498)
8. G.S. Hill 2008 Hypertensive nephrosclerosis Curr Opin Nephrol Hypertens 17 266 270 10.1097/MNH.0b013e3282f88a1f 18408477
9. T.H. Jafar P.C. Stark C.H. Schmid, et al. 2003 Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis Ann Intern Med 139 244 252 1:CAS:528:DC%2BD3sXnt12kurs%3D 12965979
10. J.C. Peterson S. Adler J.M. Burkart, et al. 1995 Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 754 762 1:STN:280:DyaK28%2FjtVOntw%3D%3D 7574193
11. P.A. Sarafidis G.L. Bakris 2006 Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease Nephrol Dial Transplant 21 2366 2374 10.1093/ndt/gfl309 16782993 (Pubitemid 44644505)
12. W.Y. So A.P. Kong R.C. Ma, et al. 2006 Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients Diabetes Care 29 2046 2052 10.2337/dc06-0248 16936151 (Pubitemid 44871185)
13. J.M. Flack K. Duncan S.E. Ohmit, et al. 2007 Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy Vasc Health Risk Manag 3 1029 1037 1:CAS:528:DC%2BD1cXhtFKqsbw%3D 18200821
14. KDOQI 2007 KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease Am J Kidney Dis 49 S12 S154 10.1053/j.ajkd.2006.12.005 (Pubitemid 46185743)
15. I. Duka G. Bakris 2008 Influence of microalbuminuria in achieving blood pressure goals Curr Opin Nephrol Hypertens 17 457 463 10.1097/MNH. 0b013e328309a497 1:CAS:528:DC%2BD1cXhtVejtbnI 18695385
16. M.D. Solbu T.G. Jenssen B.O. Eriksen I. Toft 2009 Changes in insulin sensitivity, renal function, and markers of endothelial dysfunction in hypertension-the impact of microalbuminuria: a 13-year follow-up study Metabolism 58 408 415 10.1016/j.metabol.2008.10.016 1:CAS:528: DC%2BD1MXitVClsbw%3D 19217459
17. G. Dell'Omo G. Penno L. Pucci, et al. 2007 Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men J Hypertens 25 389 1395 10.1097/HJH.0b013e3281268548 (Pubitemid 46918825)
18. J. Lea T. Greene L. Hebert, et al. 2005 The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension Arch Intern Med 165 947 953 10.1001/archinte.165.8.947 15851648 (Pubitemid 40563243)
19. W.B. Eijkelkamp Z. Zhang G. Remuzzi, et al. 2007 Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial J Am Soc Nephrol 18 1540 1546 10.1681/ASN.2006050445 1:CAS:528:DC%2BD2sXls1Glu7Y%3D 17409317 (Pubitemid 46717521)
20. A.V. Chobanian G.L. Bakris H.R. Black, et al. 2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 1206 1252 10.1161/01.HYP.0000107251.49515.c2 1:CAS:528:DC%2BD3sXpsVGisL4%3D 14656957 (Pubitemid 37553153)
21. G. Mancia B.G. De A. Dominiczak, et al. 2007 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 1105 1187 10.1097/HJH.0b013e3281fc975a 1:CAS:528:DC%2BD2sXmtlWnsr0%3D 17563527 (Pubitemid 46924065)
22. M.J. Sarnak T. Greene X. Wang, et al. 2005 The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study Ann Intern Med 142 342 351 15738453
23. R.W. Schrier R.O. Estacio P.S. Mehler W.R. Hiatt 2007 Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Nat Clin Pract Nephrol 3 428 438 10.1038/ncpneph0559 17653121 (Pubitemid 47123588)
24. B.M. Brenner M.E. Cooper de Zeeuw, et al. 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 869 10.1056/NEJMoa011161 1:CAS:528: DC%2BD3MXntlelsLk%3D 11565518 (Pubitemid 34940825)
25. F.F. Hou D. Xie X. Zhang, et al. 2007 Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency J Am Soc Nephrol 18 1889 1898 10.1681/ASN.2006121372 1:CAS:528:DC%2BD2sXnt1WjsL0%3D 17494885 (Pubitemid 46870325)
26. E.J. Lewis L.G. Hunsicker W.R. Clarke, et al. 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 851 860 10.1056/NEJMoa011303 1:CAS:528:DC%2BD3MXntlelsLg%3D 11565517 (Pubitemid 34940824)
27. H.H. Parving F. Persson J.B. Lewis, et al. 2008 Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2433 2446 10.1056/NEJMoa0708379 1:CAS:528:DC%2BD1cXmvFKmtLY%3D 18525041 (Pubitemid 351793017)
28. J.T. Wright Jr G. Bakris T. Greene, et al. 2002 Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 2421 2431 10.1001/jama.288.19.2421 1:CAS:528:DC%2BD38XoslOktr8%3D 12435255 (Pubitemid 35340538)
29. Summary of revisions for the 2009 Clinical Practice Recommendations [no authors listed]. Diabetes Care 2009, 32(Suppl 1):S1-S35.
30. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) [no authors listed]. Lancet 1997, 349:1857-1863.
31. A. Sato T. Saruta J.W. Funder 2006 Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection Hypertens Res 29 211 216 10.1291/hypres.29.211 1:CAS:528:DC%2BD28Xms1OgtLk%3D 16778327 (Pubitemid 43853266)
32. M. Rahman S. Pressel B.R. Davis, et al. 2005 Renal outcomes in high-risk hypertensive patients treated with an angiotensinconverting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med 165 936 946 10.1001/archinte.165.8.936 1:CAS:528:DC%2BD2MXktlCjtLY%3D 15851647 (Pubitemid 40563242)
33. J.P. Casas W. Chua S. Loukogeorgakis, et al. 2005 Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis Lancet 366 2026 2033 10.1016/S0140-6736(05)67814-2 1:CAS:528:DC%2BD2MXht12ku7nJ 16338452 (Pubitemid 41773378)
34. P.A. Sarafidis P.C. Stafylas A.I. Kanaki A.N. Lasaridis 2008 Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis Am J Hypertens 21 922 929 10.1038/ajh.2008.206 1:CAS:528:DC%2BD1cXovVClu70%3D 18535536
35. R. Kunz C. Friedrich M. Wolbers J.F. Mann 2008 Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 30 48 17984482
36. S. Yusuf K.K. Teo J. Pogue, et al. 2008 Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 1547 1559 10.1056/NEJMoa0801317 1:CAS:528:DC%2BD1cXksF2isLs%3D 18378520
37. J.F. Mann R.E. Schmieder M. McQueen, et al. 2008 Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 547 553 10.1016/S0140-6736(08)61236-2 1:CAS:528:DC%2BD1cXpvFKgsLs%3D 18707986
38. P.A. Sarafidis G.L. Bakris 2008 Renin-angiotensin blockade and kidney disease Lancet 372 511 512 10.1016/S0140-6736(08)61212-X 18707969
39. L.F. Fried W. Duckworth J.H. Zhang, et al. 2009 Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D) Clin J Am Soc Nephrol 4 361 368 10.2215/CJN.03350708 1:CAS:528:DC%2BD1MXjslagur8%3D 19118120
40. A. Bidani 2006 Controversy about COOPERATE ABPM trial data Am J Nephrol 26 629 632 10.1159/000098196 17236263
41. A.S. Bomback A.V. Kshirsagar M.A. Amamoo P.J. Klemmer 2008 Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review Am J Kidney Dis 51 199 211 10.1053/j.ajkd.2007.10.040 18215698
42. M. Epstein G.H. Williams M. Weinberger, et al. 2006 Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes Clin J Am Soc Nephrol 1 940 951 10.2215/CJN.00240106 1:CAS:528: DC%2BD28XpvFOqsLk%3D 17699311
43. N. Khosla R. Kalaitzidis G.L. Bakris 2009 Predictors of hyperkalemia risk following hypertension control with aldosterone blockade Am J Nephrol 30 418 424 10.1159/000237742 1:CAS:528:DC%2BD1MXhsVensLjN 19738369
44. F.F. Hou D. Xie X. Zhang, et al. 2007 Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency J Am Soc Nephrol 18 1889 1898 10.1681/ASN.2006121372 1:CAS:528:DC%2BD2sXnt1WjsL0%3D 17494885 (Pubitemid 46870325)
45. K. Rossing K.J. Schjoedt B.R. Jensen, et al. 2005 Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 1190 1198 10.1111/j.1523-1755.2005.00511.x 1:CAS:528:DC%2BD2MXhtVCjt73E 16105050 (Pubitemid 43246436)
46. R.E. Schmieder A.U. Klingbeil E.H. Fleischmann, et al. 2005 Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study J Am Soc Nephrol 16 3038 3045 10.1681/ASN. 2005020138 1:CAS:528:DC%2BD2MXhtFegtLnF 16120821 (Pubitemid 44743501)
47. F.F. Hou X. Zhang G.H. Zhang, et al. 2006 Efficacy and safety of benazepril for advanced chronic renal insufficiency N Engl J Med 354 131 140 10.1056/NEJMoa053107 1:CAS:528:DC%2BD28XisFWitQ%3D%3D 16407508 (Pubitemid 43076710)